Combination of IRS / STAT3 dual modulators and anticancer drugs for cancer treatment

摘要

The present invention relates to a method for the treatment and / or prophylaxis of hyperlipidemia, comprising administering to a subject a dual modulator of an insulin receptor substrate (IRS) and a transcriptional signaling agent and activator 3 (Stat3) in combination with (i) a modulator of a protein kinase (PK) selected from epidermal growth factor inhibitor (EGFR inhibitor) and EGFR antibody; (ii) inhibitors of mammalian targets (mTOR) of rapamycin; (iii) mitogen-activated protein kinase (MEK) inhibitors; (iv) mutated B-Raf inhibitors; (v) chemotherapeutic agents such as gemcitabine, 5-FU, irinotecan and oxaliplatin; And (vi) in combination with some of these combinations. The combination can be used to treat a tumor that is resistant to an EGFR inhibitor, an EGFR antibody, an mTOR inhibitor, a MEK inhibitor, a mutated B-Raf inhibitor, a chemotherapeutic agent, and some combination thereof, Prevention of tumor acquired resistance to any one of the agonists, or prevention of tumor recurrence due to discontinuation of treatment with any of the above inhibitors or agonists or a combination thereof. The combination provides at least an additional and preferably synergistic therapeutic effect. The present invention also relates to cancer therapy using combination therapies that include dual modulators of IRS and Stat3 in combination with an immunotherapeutic agent. The combination can be used to screen tumors for immunotherapy.